Donor NKG2C Genotype Shapes CMV Control After Haploidentical Transplantation
Cytomegalovirus remains one of the most consequential infectious threats after allogeneic hematopoietic stem cell transplantation, especially when immune reconstitution is incomplete and antiviral pressure is uneven. In this study, donor genetics emerged as more than a background variable. NKG2C homozygosity in the donor was linked to better clearance of CMV after haploidentical transplantation, with the effect tracking closely with the recovery of adaptive NKG2C+ natural killer cells.
The signal was biologically coherent from the start. Adaptive NK cells are known to expand during CMV reactivation, and the receptor encoded by NKG2C is a key component of that response. When that gene is deleted in the donor, the transplanted immune system appears to rebuild with less capacity for the kind of rapid, expansion-driven surveillance needed to contain CMV. The practical consequence is a weaker antiviral arm at exactly the time the host is most vulnerable.
Adaptive NK-Cell Reconstitution Was Weaker With Donor NKG2C Deletion
Two cohorts were used to examine how donor NKG2C genotype related to NKG2C+ NK-cell reconstitution and CMV infection. Multivariate analysis identified donor NKG2C gene deletion as an independent prognostic factor for CMV reactivation and for refractory CMV reactivation. In other words, the genetic status of the donor did not simply correlate with infection risk in a superficial way; it retained predictive value after adjustment in the statistical model.
A second layer of the finding was even more instructive. Both the quantitative and qualitative recovery of adaptive NKG2C+ NK cells were significantly lower in recipients of grafts from NKG2Cwt/del donors than in recipients of grafts from NKG2Cwt/wt donors. Anti-CMV function followed the same pattern. The immune deficit was not limited to cell number alone; the cells that did emerge were less fully restored in function. In transplant immunology, that combination often matters more than any single readout, because a numerically present population may still fail if cytotoxic capacity, activation state, or clonal fitness is impaired.
Day 30 data sharpened the clinical picture. Patients with treatment-refractory CMV reactivation had significantly lower quantitative reconstitution of NKG2C+ NK cells than patients without CMV reactivation and those with nonrefractory reactivation. Early immune recovery therefore appears to be a discriminating marker of who can contain CMV and who cannot. The timing is clinically important because the first month after transplantation is a period of intense vulnerability, when even modest differences in innate immune recovery can change the trajectory from transient viremia to persistent, difficult-to-control infection.
Refractory CMV Tracked With an Immune Reconstitution Deficit
The outcome pattern points to a straightforward mechanistic pathway. Donor NKG2C homozygosity appears to support the quantitative and qualitative reconstruction of adaptive NK cells after haploidentical transplantation, and that reconstruction improves CMV clearance. When the donor carries a deletion allele, the transferred immune system may still reconstitute, but it does so with less depth and less functional reserve. CMV then gains a wider window for replication, persistence, and refractoriness.
The study’s survival-style incidence curves supported this association across genotype strata. CMV reactivation and refractory CMV reactivation diverged according to donor NKG2C status, and the differences were visible early enough to be clinically meaningful rather than merely statistical. A one-sentence summary from the bedside: donor genotype influenced whether the post-transplant immune system looked prepared for CMV or biologically underbuilt.
Humanized Mouse Experiments Reinforced the Clinical Pattern
The experimental arm in humanized CMV-infected mice made the human findings more credible. Adaptive NKG2C+ NK cells from NKG2Cwt/wt donors induced earlier and stronger expansion of NKG2C+ NK cells in vivo, and they drove earlier and stronger CMV clearance than cells from NKG2Cwt/del donors. The direction of effect matched the clinical data precisely.
This matters because it links genotype to mechanism rather than stopping at association. If donor NKG2C homozygosity helps seed a more vigorous adaptive NK-cell response, then the transplant recipient inherits not just hematopoietic stem cells but a more capable antiviral program. The biology is especially plausible in haploidentical transplantation, where delayed or incomplete immune recovery leaves innate defenses carrying much of the early burden against viral opportunists.
Transplant Selection May Need to Consider Innate Immune Genetics
The findings raise a concrete question for donor evaluation in haploidentical transplantation: should NKG2C genotype influence donor selection when multiple candidates are otherwise acceptable? The study does not answer that decisively, but it does show that donor genetics can shape a clinically relevant infection endpoint through adaptive NK-cell recovery. For centers managing frequent CMV complications, that opens a path toward more refined risk stratification.
Any application will need caution. Donor selection in transplantation is rarely governed by a single immune variable, and CMV risk sits alongside graft compatibility, donor availability, and the broader transplant plan. Still, this work supports a more granular view of donor biology. A donor who appears equivalent on standard criteria may differ materially in the ability to rebuild CMV-directed immunity after infusion.
The article leaves the field with a focused translational challenge rather than a broad slogan. Prospective validation will be needed to determine how strongly donor NKG2C status should influence decision-making, whether the effect holds across transplant platforms, and whether early NK-cell monitoring can identify patients who need intensified surveillance or preemptive intervention before refractory CMV becomes entrenched.